Shuqing Wang, Ph.D.

Shuqing Wang, PhD

Assosciate Professor

Department of Medicinal Chemistry, School of Pharmacy

Tianjin Medical  University

22 Qixiangtai Road

Tianjin 3000078

Email: wangshuqing@tmu.edu.cn

Education

Ph.D.  Tianjin University, Tianjin, China, 2008

M.S.    Tianjin Normal University, Tianjin, China,2005

B.S.     WuHa Institute of Technology, 1999

Professional Experience

2010-2018     Instructor, Department of Pharmacy, Tianjin Medical University, Tianjin, China

2014-2015     Visiting Scholar, Harvard Medical School, Boston, USA

2019-    Associate Professor, Department of Pharmacy, Tianjin Medical University, Tianjin, China

Research interests

Dr. Shuqing Wang is engaged in the research of drug molecular design, discovery and confirmation of new drug targets and ligand-induced conformational changes by using the new methods and technologies of biology, chemistry, computer and informatics. We seek to develop systematic current molecular simulation, drug design and optimization methods and techniques, including biological macromolecular system of large-scale, high-throughput virtual screening method, molecular dynamics simulation, virtual combinatorial library design method and ADMET analysis. The recent research focused on the protein and protein interaction mechanism, especially in the study of transmembrane protein and its inhibitors.

Publication

1. Yaqing Yang, Encheng Xie, Lingyu Du, Yu Yang, Bin Wu, Liming Sun, Shuqing Wang*and Bo OuYang *, Positive Charges in the Brace Region Facilitate the Membrane Disruption of MLKL-NTR in Necroptosis, Molecules 2021, 26, 5194

2. Shukun Wei, Xiaoyou Hu , Lingyu Du , Linlin Zhao, Hongjuan Xue5, Chaolun Liu, James J. Chou, Jin Zhong, Yimin Tong,*, Shuqing Wang,* and Bo OuYang,*Inhibitor Development against p7 Channel in Hepatitis C Virus, Molecules 2021, 26, 1350

3. Xue-Qing Song , Rui-Ping Liu , Shu-Qing Wang , Zhe Li , Zhong-Ying Ma , Ran Zhang , Cheng-Zhi Xie , Xin Qiao , Jing-Yuan Xu, Anticancer Melatplatin Prodrugs: High Effect and Low Toxicity, MT1-ER-Target and Immune Response In Vivo, J Med Chem. 2020 Jun 11;63(11).

4. Zhou, Ping; Liang, Xingmei; Zhou, Ce; Qin, Jiaqi; Hou, Chunyu; Zhu, Zhiyan; Zhang, Wenxue; Wang, Shuqing*; Zhong, Diansheng*; Glutamine-beta-cyclod extrin for targeted doxorubicin delivery to triple-negative breast cancer tumors via the transporter ASCT2, Journal of Materials Chemistry B, 2019, 7(35): 5363-5375

5. Shichao Pang, Rongcheng Zhao, Shuqing Wang* & Jingfang Wang*,Cyclopeptides design as blockers against HCV p7 channel in silico, Volume 45,issue 17, 2019 -Pages 1419-1425.

6. Rui Liu, Jing Liu, Shuqing Wang, Yinsong Wang, Tao Zhang, Yang liu, Xin Geng and Feng Wang, Combined treatment with emodin and a telomerase inhibitor induces significant telomere damage/dysfunction and cell death, Cell Death Dis. 2019 Jul 11;10(7):527. doi: 10.1038/s41419-019-1768-x.

7. Si-Yu Long, Qi-Shi Du *, Shu-Qing Wang ,* Pei-Duo Tang,*, Da-Peng Li c,Ri-Bo Huang, Graphene two-dimensional crystal prepared from cellulose twodimensional crystal hydrolysed from sustainable biomass sugarcane bagasse. Journal of Cleaner Production 241 (2019) 118209.

8. Cao C, Wang S,  Cui T, Su XC, Chou JJ: Ion   and inhibitor binding of the double-ring ion  selectivity filter of the   Mitochondrial Calcium Uniporter. PNAS, 2017, 114(14):  E2846-E2851.

9. Zhao L, Wang S,  Zhu Q, Wu B, Liu Z, OuYang   B, Chou JJ: Specific Interaction of the Human  Mitochondrial Uncoupling   Protein 1 with Free Long-Chain Fatty Acid. Structure,  Volume 25, Issue   9, 5 September 2017, Pages 1371-1379.e3

10. 3.Zhao L#, Wang S#, Du L, Dev J, Zhou L, Liu Z, Chou   JJ*, OuYang  B*: Structural basis of interaction between the hepatitis C   virus p7 channel  and its blocker hexamethylene amiloride. Protein Cell,   2016,7(4):300-4. (Co-first  author)

11. 4.Zhao L#, Wang S#, Run C, Ouyang B*, Chou JJ*:   Specific Lipid  Binding of Membrane Proteins in Detergent Micelles Characterized   by NMR and  Molecular Dynamics. Biochemistry, 2016, 55(38):5317-20.   (Co-first  author)

12. Du QS*, Wang SQ, Chen D, Meng JZ, Huang RB. In depth analysis on the binding sites of adamantane derivatives in HCV (hepatitis C virus) p7 channel based on the NMR structure. PLoS One. 2014 Apr 8;9(4):e93613.

13. Wei-Bing Zhang^#, Wen-Bo Liu^#, Jing-Wei Wu, Wei-Li Dong, Shu-Qing Wang* & Run-Ling Wang*, The derivatives of oseltamivir design passing through the important cleft of neuraminidase against influenza virus by de novo design. Molecular Simulation. Published online: 06 Dec 2013

14. Jing Gao, Xiao-Hui Wu, Wei-Li Dong and Shu-Qing Wang*, A Series of Propofol Analogs Design by Targeting Pentameric Ligand-gated Ion Channel In Silico Method. Protein & peptide Letter, 2013,20,1238-1245.

15. Liu L, Ma Y, Wang RL, Xu WR, Wang SQ*, Chou KC, Find novel dual-agonist drugs for treating type 2 diabetes by means of cheminformatics, Drug Design, Development and Therapy, April 2013 Volume 2013:7 Pages 279 – 288.

16. Ma Y, Sun SX, Cheng XC, Wang SQ, Dong WL, Wang RL, Xu WR., Design and synthesis of imidazolidine-2,4-dione derivatives as selective inhibitors by targeting protein tyrosine phosphatase-1B over T-cell protein tyrosine phosphatase. Chem Biol Drug Des. 2013 Nov;82(5):595-602.

17. Ying Ma, Shuqing Wang*, Wei-Ren Xu, Run-ling Wang*, Kuo-Chen Chou, Design Novel Dual Agonists for Treating Type-2 Diabetes by Targeting Peroxisome Proliferator-Activated Receptors with Core Hopping Approach, PLoS One, 7( 6): e38546, 2012.

18. Zhang LS, Wang SQ, Xu WR, Wang RL*, Wang JF*. Scaffold-based pan-agonist design for the PPARα, PPARβ and PPARγ receptors, PLoS One, 7(10):e48453, 2012. (co-first authors)

19. Du QS, Gao J, Wei YT, Du LQ, Wang SQ*, Huang RB, Structure-Based and Multiple Potential Three-Dimensional Quantitative Structure-Activity Relationship (SB-MP-3D-QSAR) for Inhibitor Design, J. Chem. Inf. Model., 52 (4), 996–1004, 2012.

20. Xiao-Bo Li, Shu-Qing Wang*, Wei-Ren Xu, Run-Ling Wang*, Kuo-Chen Chou, Novel Inhibitor Design for Hemagglutinin against H1N1 Influenza Virus by Core Hopping Method, 6(11): e28111, 2011.

21. Liu Xu-Yuan, Wang Run-Ling*, Xu Wei-Ren, Tang Li-Da, Wang Shu-Qing*, Chou Kuo-Chen, Docking and Molecular Dynamics Simulations of Peroxisome Proliferator Activated Receptors Interacting with Pan Agonist Sodelglitazar. Protein and Peptide Letters, 18(10): 1021-1027, 2011.

22. Shu-Qing Wang*, Xian-Chao Cheng, Wei-Li Dong, Run-Ling Wang*, Kuo-Chen Chou, Three new powerful oseltamivir derivatives for inhibiting the neuraminidase of influenza virus. Biochemical and Biophysical Research Communications, 2010, 401:188-191, 2010.

23. Qi-Shi Du*, Ri-Bo Huang, Shu-Qing Wang, Kuo-Chen Chou, Designing Inhibitors of M2 Proton Channel against H1N1 Swine Influenza Virus. PLoS ONE, February, 5(2): e9388: 1-7, 2010.

24. Qi-Shi Du*, Shu-Qing Wang, Ri-Bo Huang, Kuo-Chen Chou,Computational 3D structures of drug-targeting proteins in the 2009-H1N1 influenza A virus. Chemical Physics Letters, 485,191-195, 2010.

25. Du QS, Huang RB, Wang SQ, Chou KC, Designing Inhibitors of M2 Proton Channel against H1N1 Swine Influenza Virus, PLoS One. 2010 Feb 23;5(2):e9388.

Grant

Project of the national natural science foundation of China, 21772146, Research on anti-hepatitis c virus inhibitors based on p7 3D nuclear magnetic structure, 2018-2021, in progress, Project leader.